![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics (PK) and PK-Pharmacodynamic (PD) Relationship of Dolutegravir (DTG) in Integrase Inhibitor (INI)-Naive Subjects
|
|
|
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
Ivy Song,1 Shuguang Chen,2 Stephen Piscitelli,3 Sherene Min3
1Clinical Pharmacology Modeling & Simulation, 2Clinical Statistics, 3Infectious Diseases Therapeutic Area Unit, GlaxoSmithKline, Research Triangle Park, NC, USA
![ICAAC1.gif](../images/091613/091613-5/ICAAC1.gif)
![ICAAC2.gif](../images/091613/091613-5/ICAAC2.gif)
![ICAAC3.gif](../images/091613/091613-5/ICAAC3.gif)
![ICAAC4.gif](../images/091613/091613-5/ICAAC4.gif)
![ICAAC5.gif](../images/091613/091613-5/ICAAC5.gif)
![ICAAC6.gif](../images/091613/091613-5/ICAAC6.gif)
![ICAAC7.gif](../images/091613/091613-5/ICAAC7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|